

Freedom of Information Request**Ref: UHB 18-222**

Date 1 May 2018

By Email

Dear Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

- Please provide the following information relating to NSCLC[1] patients treated[2] by your Trust in the 3 months, December 2017 to February 2018 inclusive. If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.**

We are unable to provide the number of Stage IIIB/IV NSCLC patients as this information is not reliably recorded on our database system. We are however able to confirm that the total number of NSCLC patients was 43, as shown in the table below.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV patients treated, please indicate the level at which the data has been provided.	
Patients with NSCLC Stage IIIB/IV	Please see above statement.	Total Number NSCLC Patients	43
		Other (please specify)	-
		Data not held/Accessible	-

- Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies. If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:**

We are unable to provide the number of Stage IIIB/IV NSCLC patients as this information is not reliably recorded on our database system. The information we are providing therefore refers to the total number of NSCLC patients treated with the following therapies listed in the table below.

Please note where the figures are fewer than 5, this has been denoted by **. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would

breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information.

	Total Number of NSCLC patients
Docetaxel (mono or combination therapy)	**
Atezolizumab (Tecentriq)	**
Nivolumab (Opdivo)	**
Pembrolizumab (Keytruda)	38

3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Not applicable.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
 University Hospitals Bristol NHS Foundation Trust
 Trust Headquarters
 Marlborough Street
 Bristol
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,


FOI Administrator